跳至主要内容
临床试验/NCT07349459
NCT07349459尚未招募不适用

Clinical Study Evaluating Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin

Tanta University1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2026年4月30日最近更新:
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
90
试验地点
1
主要终点
Decreasing incidence and severity of cardiotoxicity

研究概览

简要总结

This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.

详细描述

Doxorubicin is one of the most potent chemotherapeutic agents and is widely used for the treatment of various cancers and hematological malignancies . Although Doxorubicin has a potential beneficial effect in cancer treatment, its dose-dependent cardio toxicity is considered a major challenge.

Doxorubicin is known to generate free radicals either by redox cycling between a semiquinone form and a quinone form or by forming a Doxorubicin-Fe3+ complex . In both pathways, molecular oxygen is reduced to superoxide ion , which is converted to other forms of reactive oxygen species such as hydrogen peroxide and hydroxyl radical . These free radicals could then cause membrane and macromolecule damage, both of which lead to injury to the heart, an organ that has a relatively low level of antioxidant enzymes such as superoxide dismutase and catalase .

Furthermore, it was revealed that Doxorubicin may enhance the death of cardiomyocytes by affecting the tumor necrosis factor signaling pathway via increasing the expression and levels of inflammatory genes interleukin and interleukin -6 .

To alleviate DOX-induced toxicity, researchers have tested a number of strategies, including the administration of antioxidants and/or antiapoptotic agents, in both in vitro and in vivo models of Doxorubicin induced cytotoxicity, but most of these trials have failed to translate into clinical benefits . As a result, there are no effective approaches for alleviating Doxorubicin induced cytotoxicity despite intensive research over recent decades .

Melatonin is a natural hormone that is primarily secreted by the pineal gland and functions as a major regulator of circadian rhythms in humans . Melatonin also plays a variety of biological roles as a modulator of mood, sexual behavior and sleep; low levels or a deficiency of melatonin are also associated with Parkinson's disease, Alzheimer's disease, epilepsy, ischemic injury, diabetes, and even cancer .

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Age from 18 to 65 years old.
  • Gender: female.
  • Positive breast cancer women who are scheduled to receive Doxorubicin.
  • Have a good performance status according to the eastern cooperative oncology group with a score of 0-
  • Normal baseline Echocardiography with left ventricular ejection fraction ≥ 50%.
  • Normal renal and liver function tests.

排除标准

  • Pregnant or breastfeeding women.
  • Women with HER-2 positive of breast cancer.
  • Formerly treated with Doxorubicin.
  • Patients with a known hypersensitivity to any of the used drugs.
  • On other concomitant vitamins or food supplements.
  • Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy.
  • Impaired Left ventricular systolic function in which the Left Ventricular Ejection Fraction < 50%.

研究组 & 干预措施

Group 1 (Doxorubicin group)

Placebo Comparator

30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks.

干预措施: Group 1 (Doxorubicin group) (Drug)

Group 2 (Vitamin D group)

Experimental

patients with Vitamin D supplementation (1000 iu/day) plus Doxorubicin for 12 weeks

干预措施: Group 2: Vitamin D group (Drug)

Group 3 (melatonin group)

Experimental

30 patients with 10 mg of melatonin orally, once daily plus Doxorubicin for 12 weeks.

干预措施: Group 3: melatonin group (Drug)

结局指标

主要结局

Decreasing incidence and severity of cardiotoxicity

时间窗: 12 weeks

Assessment of decreasing incidence and severity of cardiotoxicity by echocardiogram and ejection fraction is associated with doxorubicin treatment.

次要结局

  • change in the serum level of the (biological markers).(12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Majed Essa Alharbi

Resident

Tanta University

研究点 (1)

Loading locations...

相似试验